Like patients differ, tumors tend to respond differently once exposed to prior lines of therapies. Exploring situations of disease progression after second-line treatment leads to considering a ‘re-challenge’ with drug combinations that have shown positive impact in the first line (FOLFOX, FOLFIRI and FOLFOXIRI). Other drugs like regorafenib or trifluridine-tipiracil are also available options. IndiTreat® CRC Extend provides information about the sensitivity of an individual patient’s tumoroids to the drugs and combinations used in third- and further-lines of systemic antineoplastic treatment. Please request our product sheet for IndiTreat® CRC Extend for details on the test, or take a look at www.inditreat.com. IndiTreat® CRC Extend – Drug panel Ordering Code: 2CX-01-CRC-01 FOLFOX regorafenib FOLFIRI trifluridine + tipiracil FOLFOXIRI IndiTreat® CRC Explore provides a rationale for off-label use of selected antineoplastics for treating further-line mCRC patients. It is suitable for those with tumor progression after at least two previous lines of systemic therapy and who may receive ’re-challenge’ therapy to which their tumors responded in firstline treatment. Therapeutic strategies with approved off-label drug regiments such as mitomycin C plus fluorouracil, for example, are also considered. IndiTreat® CRC Explore – Drug panel Ordering Code: 2CX-01-CRC-03 trifluridine-tipiracil mitomycin + 5FU regorafenib temozolamide + irinotecan gemcitabine + 5FU IndiTreat® CRC Start – Drug panel Ordering Code: 2CX-01-CRC-02 5-fluorouracil (5FU) FOLFIRI FOLFOX FOLFOXIRI Clinical data suggest that some patients respond better to FOLFOX followed by FOLFIRI while others respond better to FOLFIRI followed by FOLFOX, with significant differences in terms of long-term outcomes when the “right” sequence is chosen for an individual patient1. The IndiTreat® CRC Start test panel provides information about the sensitivity of a patient’s tumoroids to the typical drug combinations in first-line. Please request our product sheet for IndiTreat® CRC Start for details on the test, or take a look at www.inditreat.com. Sequence matters – get the best possible Start to maximise patient benefit Extend therapy decision-making boundaries for third- and further-line mCRC patients Explore additional options for third- and further-line patients 1 Abraham J P et al.: Clin Cancer Res. 2021; 27: 1174-8. https://doi: 10.1158/1078-0432.CCR-20-3286
RkJQdWJsaXNoZXIy ODY1MjQ=